细胞外HMGB1通过损害调节性T细胞稳定性加剧1型糖尿病的自身免疫进展与复发
该研究以NOD小鼠为模型,发现中和HMGB1可延迟糖尿病发病,并使20只新发糖尿病NOD小鼠中的13只糖尿病逆转;HMGB1通过激活RAGE和TLR4增强PI3K-Akt-mTOR信号,损害调节性T细胞(Treg)的稳定性和功能。1型糖尿病患者循环HMGB1水平升高与Treg不稳定性相关,提示阻断HMGB1可能成为1型糖尿病的治疗靶点。
要点
- 中和HMGB1可延迟NOD小鼠糖尿病发病,并使20只新发糖尿病小鼠中13只糖尿病逆转。
- HMGB1通过激活RAGE和TLR4增强PI3K-Akt-mTOR信号,损害Treg稳定性和功能。
- 1型糖尿病患者循环HMGB1水平升高与Treg不稳定性相关,提示HMGB1可能为治疗靶点。
核心结论
- 数据支持HMGB1可能成为预防1型糖尿病自身免疫启动、进展和复发的可行治疗靶点。
研究设计与样本
- 采用NOD小鼠模型,研究阻断HMGB1对1型糖尿病预防、治疗和逆转的影响。
- 使用携带Foxp3谱系报告构建体的转基因报告小鼠研究HMGB1对Treg的影响。
- 研究HMGB1刺激下Treg特征及相关信号通路,并探讨结果与人类自身免疫性糖尿病的相关性。
主要发现
- 中和HMGB1延迟糖尿病发病,并使20只新发糖尿病NOD小鼠中的13只糖尿病逆转。
- 阻断HMGB1可防止糖尿病NOD小鼠的胰岛同种移植物遭受自身免疫攻击。
- 给予HMGB1损害Treg稳定性和功能。
- HMGB1激活RAGE和TLR4,增强PI3K-Akt-mTOR信号,从而损害Treg稳定性和功能。
- 1型糖尿病患者循环HMGB1水平升高与Treg不稳定性相关。
临床怎么用
- 原文结论提示HMGB1可能是预防1型糖尿病自身免疫启动、进展和复发的可行治疗靶点,但原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: High-mobility group box 1 (HMGB1), an evolutionarily conserved chromosomal protein, was rediscovered to be a 'danger signal' (alarmin) that alerts the immune system once released extracellularly. Therefore, it has been recognised contributing to the pathogenesis of autoimmune diabetes, but its exact impact on the initiation and progression of type 1 diabetes, as well as the related molecular mechanisms, are yet to be fully characterised. METHODS: In the current report, we employed NOD mice as a model to dissect the impact of blocking HMGB1 on the prevention, treatment and reversal of type 1 diabetes. To study the mechanism involved, we extensively examined the characteristics of regulatory T cells (Tregs) and their related signalling pathways upon HMGB1 stimulation. Furthermore, we investigated the relevance of our data to human autoimmune diabetes. RESULTS: Neutralising HMGB1 both delayed diabetes onset and, of particular relevance, reversed diabetes in 13 out of 20 new-onset diabetic NOD mice. Consistently, blockade of HMGB1 prevented islet isografts from autoimmune attack in diabetic NOD mice. Using transgenic reporter mice that carry a Foxp3 lineage reporter construct, we found that administration of HMGB1 impairs Treg stability and function. Mechanistic studies revealed that HMGB1 activates receptor for AGE (RAGE) and toll-like receptor (TLR)4 to enhance phosphatidylinositol 3-kinase (PI3K)-Akt-mechanistic target of rapamycin (mTOR) signalling, thereby impairing Treg stability and functionality. Indeed, high circulating levels of HMGB1 in human participants with type 1 diabetes contribute to Treg instability, suggesting that blockade of HMGB1 could be an effective therapy against type 1 diabetes in clinical settings. CONCLUSIONS/INTERPRETATION: The present data support the possibility that HMGB1 could be a viable therapeutic target to prevent the initiation, progression and recurrence of autoimmunity in the setting of type 1 diabetes.
引用
- Zhang J, Chen L, Wang F, et al. Extracellular HMGB1 exacerbates autoimmune progression and recurrence of type 1 diabetes by impairing regulatory T cell stability. Diabetologia. 2020. PMID: 32072192. doi:10.1007/s00125-020-05105-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。